Fortress Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Fortress Biotech, Inc. (FBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 290.00 thousand shares for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2020-03-16
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2015-12-31 was 0.00 shares.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2019 was 290.00K shares, a 40.82% decline from fiscal 2018.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2018 was 490.00K shares, a 56.59% decline from fiscal 2017.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2017 was 1.13M shares, a 42.12% decline from fiscal 2016.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2016 was 1.95M shares, a 0.00% change from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|
| 2019-12-31 | 290.00K shares 10-K · filed 2020-03-16 | ||
| 2018-12-31 | 490.00K shares 10-K · filed 2020-03-16 | ||
| 2017-12-31 | 1.13M shares 10-K · filed 2019-03-18 | ||
| 2016-12-31 | 1.95M shares 10-K · filed 2017-03-16 | ||
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | 1.95M shares 10-K · filed 2016-03-15 | |
| 2015-09-30 | 1.95M shares 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |